EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Evofem Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026
- Market cap
- $865.23K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.0037 (−37.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Evofem Biosciences, Inc. grew revenue 4.5% to $18.05M over the twelve months to Jun 30, 2026. Free cash flow was -$477.00K.
Revenue
$18.05M
+4.5% vs. a year earlier
Operating income
-$2.76M
TTM Q2 2026
Free cash flow
-$477.00K
TTM Q2 2026
EPS, diluted
-$0.11
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $865.23K
- P/E ratio
- –
- Price to sales
- 0.05
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -55.13%
Fundamentals
- Revenue
- $18.05M
- Net income
- -$15.28M
- EPS, diluted
- -$0.11
- Free cash flow
- -$477.00K
- Book value per share
- -$0.64
- Diluted shares
- 137M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$18.05M+4.5% YoY
Gross profit
$13.63M-1.0% YoY
Operating income
-$2.76M
Net income
-$15.28M
EPS, diluted
-$0.11
Free cash flow
-$477.00K
Reported periodTrailing twelve months